

Anisha Doshi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/813329/publications.pdf>

Version: 2024-02-01

8
papers

220
citations

1684188

5
h-index

1720034

7
g-index

12
all docs

12
docs citations

12
times ranked

429
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2022, 98, .	1.1	31
2	A Systematic Review of Resting-State Functional MRI Connectivity Changes and Cognitive Impairment in Multiple Sclerosis. <i>Brain Connectivity</i> , 2021, , .	1.7	9
3	MS-SMART study: systematic sampling bias concerns – Authors' reply. <i>Lancet Neurology</i> , The, 2020, 19, 479-480.	10.2	0
4	NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study. <i>American Journal of Neuroradiology</i> , 2020, 41, 2209-2218.	2.4	10
5	Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. <i>Lancet Neurology</i> , The, 2020, 19, 214-225.	10.2	81
6	Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-72.	0.7	11
7	Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. <i>BMJ Open</i> , 2018, 8, e021944.	1.9	43
8	Secondary Progressive Multiple Sclerosis: Definition and Measurement. <i>CNS Drugs</i> , 2016, 30, 517-526.	5.9	34